Hellerup, Denmark, November 7, 2024 – UNION therapeutics A/S (UNION), a privately held, clinical stage, pharmaceutical development company focused on immunology, today announced that Dr. Kim Kjøller, CO-CEO of UNION will present at the seminar on Clinical and Commercial Strategy at the 8th Annual Dermatology Drug Development Summit on 12-14 November 2024, in Boston, US.
Dr. Kjøller will discuss recent trials in atopic dermatitis (AD) and the ability between outcome scales to adequately differentiate between placebo and active treatment, particularly in the segment of patients with moderate severity of AD. Data from a recent study will be used to showcase strategies to ensure consistency between Investigator Global Assessment (IGA) 0/1 (FDA’s primary endpoint for AD studies), biomarker data, patient reported improvement, and EASI scoring for patients with more severe disease. Methods to improve the quality of EASI scoring for future studies, particular in the moderate segment, will be discussed, and first supporting data will be presented.
Presentation details
Presentation: Recent trials in AD – Inconsistency between outcome scales
Presenter: Dr. Kim D. Kjøller, Co-CEO, UNION therapeutics
Date and time: Wednesday November 13, 2024, at 11:55am EST.
Contacts
Morten Boesen, Chief Financial Officer, UNION therapeutics A/S
+45 2381 5487
About UNION therapeutics
UNION therapeutics is a privately held, clinical stage, pharmaceutical development company focused on immunology. UNION’s lead asset is orismilast, a next generation, high potency PDE4B/D inhibitor, for a range of immunological diseases e.g., atopic dermatitis (AD) and hidradenitis suppurativa (HS). Orismilast holds the potential to become the first safe oral treatment in AD.
UNION is headquartered in Hellerup, Denmark, and led by an international team combining biotech entrepreneurs and seasoned pharma executives, with a track record of developing and launching more than fifteen marketed drugs. Read more at http://www.uniontherapeutics.com
